Effect of vasopressin on a porcine model of persistent pulmonary hypertension of the newborn
Reem Amer
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorYasser N. Elsayed
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Search for more papers by this authorMarjory Ruth Graham
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Departments of Anesthesia, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorAnurag S. Sikarwar
Departments of Oral Biology, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorMartha Hinton
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Search for more papers by this authorCorresponding Author
Shyamala Dakshinamurti
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Departments of Physiology, University of Manitoba, Winnipeg, Canada
Correspondence
Shyamala Dakshinamurti, MD MSc, Pediatrics and Physiology, University of Manitoba, Section of Neonatology, WS012 Women's Hospital, 735 Notre Dame Ave, Winnipeg, Canada R3E 0L8
Email: [email protected]
Search for more papers by this authorReem Amer
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorYasser N. Elsayed
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Search for more papers by this authorMarjory Ruth Graham
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Departments of Anesthesia, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorAnurag S. Sikarwar
Departments of Oral Biology, University of Manitoba, Winnipeg, Canada
Search for more papers by this authorMartha Hinton
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Search for more papers by this authorCorresponding Author
Shyamala Dakshinamurti
Section of Neonatology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada
Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada
Departments of Physiology, University of Manitoba, Winnipeg, Canada
Correspondence
Shyamala Dakshinamurti, MD MSc, Pediatrics and Physiology, University of Manitoba, Section of Neonatology, WS012 Women's Hospital, 735 Notre Dame Ave, Winnipeg, Canada R3E 0L8
Email: [email protected]
Search for more papers by this authorAbstract
Background
Persistent pulmonary hypertension of the newborn (PPHN) is due to a failure of pulmonary vascular relaxation. Vasopressin, a systemic vasoconstrictor acting on smooth muscle AVPR1a receptors, is used in treatment of PPHN. We sought to determine acute effects of vasopressin infusion on pulmonary hemodynamics in a large animal model of hypoxic PPHN.
Methods
PPHN was induced in 6 newborn piglets by 72 h normobaric hypoxia (FiO2 = 0.10); controls were 7 age-matched 3-day-old piglets. Animals were anesthetized and ventilated with central venous and arterial lines, and after stabilization, randomized using a crossover design to normoxic or hypoxic ventilation, then 30 min infusion of 0.0012 U/kg/min vasopressin, followed by 45 min vasopressin washout period. Echocardiographic parameters and oxygen consumption were measured before and after vasopressin. Relaxation to vasopressin was tested in isolated PPHN and control pulmonary arteries by isometric myography. Expression of AVPR1a receptor mRNA was quantified in arterial and myocardial tissues.
Results
Vasopressin did not alleviate hypoxia-responsiveness of PPHN pulmonary circuit. There were no significant differences in pulmonary hypertension, cardiac function indices, or oxygenation indices after vasopressin infusion. Vasopressin did not dilate control or PPHN pulmonary arteries, and AVPR1 was minimally expressed.
Conclusions
Vasopressin does not have a direct pulmonary vasodilator effect in PPHN, within the timeframe studied.
CONFLICTS OF INTEREST
No financial ties or conflicts of interest to disclose.
REFERENCES
- 1 Lakshminrusimha S, Steinhorn RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol. 1999; 26: 601–619.
- 2 Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000; 105: 14–20.
- 3 Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, Partridge JC, Rogers EE, Keller RL. Persistent pulmonary hypertension of the newborn in late preterm and term infants in california. Pediatrics. 2017; 139. pii: e20161165.
- 4 Baczynski M, Ginty S, Weisz DE, McNamara PJ, Kelly E, Shah P, Jain A. Short-term and long-term outcomes of preterm neonates with acute severe pulmonary hypertension following rescue treatment with inhaled nitric oxide. Arch Dis Child Fetal Neonatal Ed. 2017; 102: F508–F514.
- 5 Barrington KJ, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2017; 1: CD000399.
- 6 Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007; 120: e272–e282.
- 7
Sharman A,
Low J. Vasopressin and its role in critical care.
Cont Educ Anaesth Crit Care Pain.
2008; 8: 134–137.
10.1093/bjaceaccp/mkn021 Google Scholar
- 8 Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology. 2006; 105: 599–612; quiz 639–40.
- 9 Hirsch AT, Majzoub JA, Ren CJ, Scales KM, Creager MA. Contribution of vasopressin to blood pressure regulation during hypovolemic hypotension in humans. J Appl Physiol (1985). 1993; 75: 1984–1988.
- 10 Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med. 2002; 30: 1365–1378.
- 11 Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care. 2003; 7: 427–434.
- 12 Malay MB, Ashton JL, Dahl K, Savage EB, Burchell SA, Ashton RC, Jr., Sciacca RR, Oliver JA, Landry DW. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med. 2004; 32: 1327–1331.
- 13 Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest. 1993; 103: 1241–1245.
- 14 Scheurer MA, Bradley SM, Atz AM. Vasopressin to attenuate pulmonary hypertension and improve systemic blood pressure after correction of obstructed total anomalous pulmonary venous return. J Thorac Cardiovasc Surg. 2005; 129: 464–466.
- 15 Meyer S, Gottschling S, Baghai A, Wurm D, Gortner L. Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury. Crit Care. 2006; 10: R71.
- 16 Bidegain M, Greenberg R, Simmons C, Dang C, Cotten CM, Smith PB. Vasopressin for refractory hypotension in extremely low birth weight infants. J Pediatr. 2010; 157: 502–504.
- 17 Stathopoulos L, Nicaise C, Michel F, Thomachot L, Merrot T, Lagier P, Martin C. Terlipressin as rescue therapy for refractory pulmonary hypertension in a neonate with a congenital diaphragmatic hernia. J Pediatr Surg. 2011; 46: e19–e21.
- 18 Mohamed A, Nasef N, Shah V, McNamara PJ. Vasopressin as a rescue therapy for refractory pulmonary hypertension in neonates: case series. Pediatr Crit Care Med. 2014; 15: 148–154.
- 19 Malikiwi A, Sasi A, Tan K, Sehgal A. Vasopressin as an adjunct therapy for pulmonary hypertension: a case report. Eur J Pediatr. 2014; 173: 1651–1654.
- 20 Shivananda S, Ahliwahlia L, Kluckow M, Luc J, Jankov R, McNamara P. Variation in the management of persistent pulmonary hypertension of the newborn: a survey of physicians in Canada, Australia, and New Zealand. Am J Perinatol. 2012; 29: 519–526.
- 21 Dakshinamurti S, Mellow L, Stephens NL. Regulation of pulmonary arterial myosin phosphatase activity in neonatal circulatory transition and in hypoxic pulmonary hypertension: a role for CPI-17. Pediatr Pulmonol. 2005; 40: 398–407.
- 22 Hinton M, Mellow L, Halayko AJ, Gutsol A, Dakshinamurti S. Hypoxia induces hypersensitivity and hyperreactivity to thromboxane receptor agonist in neonatal pulmonary arterial myocytes. American journal of physiology. Am J Physiol Lung Cell Mol Physiol. 2006; 290: L375–L384.
- 23 McCrary AW, Malowitz JR, Hornick CP, Hill KD, Cotten CM, Tatum GH, Barker PC. Differences in eccentricity index and systolic-diastolic ratio in extremely low-birth-weight infants with bronchopulmonary dysplasia at risk of pulmonary hypertension. Am J Perinatol. 2016; 33: 57–62.
- 24 Mertens L, Seri I, Marek J, et al. Targeted neonatal echocardiography in the neonatal intensive care unit: practice guidelines and recommendations for training. Eur J Echocardiogr. 2011; 12: 715–736.
- 25 Kelly DA, Hislop AA, Hall SM, Haworth SG. Relationship between structural remodeling and reactivity in pulmonary resistance arteries from hypertensive piglets. Pediatr Res. 2005; 58: 525–530.
- 26 Rhodes J. Comparative physiology of hypoxic pulmonary hypertension: historical clues from brisket disease. J Appl Physiol (1985). 2005; 98: 1092–1100.
- 27 Snow JB, Kitzis V, Norton CE, et al. Differential effects of chronic hypoxia and intermittent hypocapnic and eucapnic hypoxia on pulmonary vasoreactivity. J Appl Physiol. 2008; 104: 110–118.
- 28 Fam BSO, Pare P, Felkl AB, et al. Oxytocin and arginine vasopressin systems in the domestication process. Genet Mol Biol. 2018; 41: 235–242.
- 29 Summanen M, Back S, Voipio J, Kaila K. Surge of peripheral arginine vasopressin in a rat model of birth asphyxia. Front Cell Neurosci. 2018; 12: 2.
- 30 Choong K, Kissoon N. Vasopressin in pediatric shock and cardiac arrest. Pediatr Crit Care Med. 2008; 9: 372–379.
- 31 Nozari A, Rubertsson S, Wiklund L. Differences in the pharmacodynamics of epinephrine and vasopressin during and after experimental cardiopulmonary resuscitation. Resuscitation. 2001; 49: 59–72.
- 32Par_Pharmaceutical_Companies. Vasostrict Vasopressin injectable product monograph. 2014 ed. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204485s003lbl.pdf: US Food and Drug Administration 2014.
- 33 Biban P, Gaffuri M. Vasopressin and terlipressin in neonates and children with refractory septic shock. Curr Drug Metab. 2013; 14: 186–192.
- 34 Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358: 877–887.
- 35 Jochberger S, Dorler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009; 37: 476–482.
- 36 Stork R, Hussoin K, Doniel S, Milliez J, Morishima H, James LS. Characteristics of Vasopressin (AVP) release during Adrenocorticotrophin (ACTH) induced parturition in the lamb. Pediatr Res. 1977; 11: 412.
- 37 Delmas A, Leone M, Rousseau S, Albanese J, Martin C. Clinical review: vasopressin and terlipressin in septic shock patients. Crit Care. 2005; 9: 212–222.
- 38 Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med. 2009; 180: 632–639.
- 39 Jin HK, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci. 1989; 298: 227–236.
- 40 Sai Y, Okamura T, Amakata Y, Toda N. Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Eur J Pharmacol. 1995; 282: 235–241.
- 41 Burkett DA, Slorach C, Patel SS, et al. Left ventricular myocardial function in children with pulmonary hypertension: relation to right ventricular performance and hemodynamics. Circ Cardiovasc Imaging. 2015; 8. pii: e003260.
- 42 Siehr SL, Feinstein JA, Yang W, Peng LF, Ogawa MT, Ramamoorthy C. Hemodynamic effects of phenylephrine, vasopressin, and epinephrine in children with pulmonary hypertension: a pilot study. Pediatr Crit Care Med. 2016; 17: 428–437.
- 43 Sarkar J, Golden PJ, Kajiura LN, Murata LA, Uyehara CF. Vasopressin decreases pulmonary-to-systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock. Shock. 2015; 43: 475–482.
- 44 Hussain A, Bennett R, Haqzad Y, et al. The differential effects of systemic vasoconstrictors on human pulmonary artery tension. Eur J Cardiothorac Surg. 2017; 51: 880–886.
- 45 Enomoto M, Pan J, Shifrin Y, Belik J. Age dependency of vasopressin pulmonary vasodilatory effect in rats. Pediatr Res. 2014; 75: 315–321.
- 46 Papaioannou VE, Stakos DA, Dragoumanis CK, Pneumatikos IA. Relation of tricuspid annular displacement and tissue Doppler imaging velocities with duration of weaning in mechanically ventilated patients with acute pulmonary edema. BMC Cardiovasc Disord. 2010; 10: 20.
- 47 Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med. 2002; 30: 2548–2552.
- 48 Liard JF. Reduced oxygen consumption induced by vasopressin in dogs depends on systemic administration. Clin Sci (Lond). 1991; 81: 751–758.
Citing Literature
